Armistice Capital’s Marker Therapeutics MRKR Stock Holding History

Armistice Capital’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-148,800	Closed	-$8.26M	–	78
2018 Q4	$8.26M	Buy	+148,800	New	+$10.8M	0.63%	34

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital's MRKR Position: Q1 2019 in Review

Armistice Capital sold out of Marker Therapeutics (MRKR) in Q1 2019, closing a stake of 148,800 shares — an estimated $8.26M sold.

Armistice Capital first reported a position in MRKR in Q4 2018 and held it in 1 quarter. The position peaked at $8.26M in Q4 2018. 56 funds tracked by Wall St. Rank hold MRKR as of Q1 2019.

Armistice Capital reported no remaining Marker Therapeutics position as of Q1 2019 after selling out during the quarter.
Armistice Capital sold 148,800 Marker Therapeutics shares in Q1 2019, an estimated $8.26M.
Armistice Capital first reported a position in Marker Therapeutics in Q4 2018 and held it in 1 quarter.
Armistice Capital's Marker Therapeutics position peaked at $8.26M in Q4 2018.
56 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.